Market research
ALVAL.PA Valbiotis SA
PA EUR Consumer Defensive
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 29M
- P/E ratio
- Not available
- Analyst target
- 1.8
- Dividend yield
- Not available
- Beta
- -0.2
Profile
Company facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- ISIN
- FR0013254851
- Market cap
- 29M
- P/E ratio
- Not available
- Analyst target
- 1.8
- Dividend yield
- Not available
- Beta
- -0.2
About
About Valbiotis SA
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. Additionally, the company offers e-commerce delivery service in Belgium and Luxembourg. Valbiotis SA was incorporated in 2014 and is based in Périgny, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ALVAL.PA discussion.
5 years, 5 months ago
Valbiotis SA is currently in a long term downtrend where the price is trading 3.7% below its 200 day moving average.
From a valuation standpoint, the stock is 94.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 14.0.
Finally, its free cash flow grew by 56.3% to $-394K since the same quarter in the previous year.
Based on the above factors, Valbiotis SA gets an overall score of 2/5.